Improving the efficacy and safety of adoptive cellular therapies

A cell and cytokine technology, used in cell culture active agents, animal cells, vertebrate cells, etc., can solve problems such as excessive stimulation and proliferation, failure of T cell reproduction, etc.

Pending Publication Date: 2021-08-20
UNIV OF SOUTHERN CALIFORNIA
View PDF10 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, administration of lymphocyte-depleting chemotherapy is associated with significant toxicity (eg, pancytopenia, fever, risk of infection, neurotoxicity) and death
Additionally, adoptively transferred T cells failed to reproduce despite administ

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Improving the efficacy and safety of adoptive cellular therapies
  • Improving the efficacy and safety of adoptive cellular therapies
  • Improving the efficacy and safety of adoptive cellular therapies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0732] The present disclosure is described in further detail with reference to the following experimental examples. These examples are provided for illustrative purposes only and are not intended to be limiting unless otherwise indicated. Accordingly, the present disclosure should in no way be construed as limited to the following examples, but rather should be construed to cover any and all modifications that become apparent as a result of the teachings presented herein.

[0733] Methods for generating and characterizing CAR-T cells, including lentivirus and retrovirus production, infection of T cells and PBMCs, culture and propagation of T cells, in vitro assays of T cell function, such as ELISA, flow cytometry, Cell death assays (e.g. Matador assay), antigen detection assays (e.g. Topanga assay) and in vivo assays are known in the literature and have been described in WO 2018 / 102795 (which is incorporated herein by reference in its entirety) .

[0734] Production of Lenti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The disclosure relates generally to the generation and use of immune effector cells (e.g., T cells, NK cells) engineered to express an immune receptor (e.g., Chimeric Antigen Receptor, Synthetic Immune Receptor, T Cell Receptor etc.) to treat a disease associated with expression of a target antigen.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Application No. 62 / 712,102, filed July 30, 2018, the disclosure of which is incorporated herein by reference in its entirety. [0003] sequence listing [0004] This application contains a Sequence Listing, which has been filed electronically in ASCII format, and is hereby incorporated by reference in its entirety. Said ASCII copy titled "SEQ-1-3059_ST25" was created on July 30, 2019, and is 4,053,956 bytes in size. technical field [0005] The present disclosure generally relates to the use of immune effector cells (eg, T cells, NK cells) genetically engineered to express chimeric antigen receptors (CARs) for the treatment of diseases associated with tumor antigen expression. Background technique [0006] Adoptive cell transfer (ACT) therapy using immune cells, particularly T cells transduced with chimeric antigen receptors (CARs) and recombinant TCRs, has shown p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/47C07K14/52
CPCA61K38/193A61K35/17A61K45/06A61K31/496A61K31/5377C07K16/2803C07K16/28C07K2317/622C07K2319/03C07K2319/33A61K2039/5156A61K2039/585C07K14/70578C07K16/2809C07K16/2875A61K2039/507C07K16/468C07K16/30C07K16/2818C07K2317/76C07K14/7051Y02A50/30C12N5/0636A61K39/001112C12N2510/00C12N2501/51C12N2501/515C12N2501/065C12N2501/2302A61K2300/00
Inventor P·M·乔杜里
Owner UNIV OF SOUTHERN CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap